BUY Glenmark Pharmaceuticals — HSBC Securities, 04 Aug 2026

BUYGlenmark Pharmaceuticals

Glenmark Pharmaceuticals share price target & all analyst calls

byHSBC SecuritiesHorizon: NA (inferred 1 year)4 Aug 2026via CNBC Awaaz.

Entry₹2,238Inferred

Target₹2,590

Total upside +15.73%

Stop lossNot given

CMP₹2,198.5Just now

Active-1.76%+17.81%upside left 10 mo left

Follow HSBC Securities for new calls(100% target hit, 23 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 4 other Long-term calls on GLENMARK See 211 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 4:56 pm IST

39 supporting11 neutral3 opposing

Supports the BUY call (39)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·21 Oct · yesterday

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) in India with Weekly Treatment Starting at ₹325

NewsGoogle News·19 Oct · 3d ago

Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors

NewsGoogle News·17 Oct · 5d ago

Glenmark stock gained 0.70 percent after US acne launch

NewsGoogle News·7 Oct · 2w ago

Glenmark Therapeutics Inc. USA has launched Pump Packs for Adapalene Gel USP, 0.1% (OTC), expanding its product portfolio in the US market.

BSE · Company Update·6 Oct · 2w ago

Neutral / worth noting (11)

Glenmark Pharmaceuticals (NSE: GLENMARK) U.S. FDA Compliance Update for Goa Facility

NewsGoogle News·23 Sept · 4w ago

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·23 Sept · 4w ago

Weighs against the BUY call (3)

Glenmark USA settles antitrust suits for $29.628 million

NewsGoogle News·18 Oct · 4d ago

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·3 Feb · 9mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from HSBC Securities

Every call and its outcome